Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy

Statistics in Biopharmaceutical Research

Volumn 7, Issue 4, 2015, Pages 348-356

  Sridhara, Rajeshwari ^a   He, Kun ^a   Nie, Lei ^a   Shen, Yuan Li ^a   Tang, Shenghui ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Expansion cohorts; Master protocols; Non proportional hazards; Treatment switch over

Indexed keywords

CARBOPLATIN; IMATINIB; PACLITAXEL; SUNITINIB;

ARTICLE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EVENT FREE SURVIVAL; HAZARD ASSESSMENT; HAZARD RATIO; HEALTH CARE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG ADENOCARCINOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; ONCOLOGY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 84950314182     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2015.1094673     Document Type: Article

References (39)

1. A.D.Barker,, C.C.Sigman,, G.J.Kelloff,, N.M.Hylton,, D.A.Berry,, and L.J.Esserman, (2009), “I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy,” Clinical Pharmacology and Therapeutics, 86, 97–100.
2. C.B.Begg, 2015Ethical Concerns About Adaptive Randomization,” Clinical Trials, 12, 101.
3. S.M.Berry,, K.R.Broglio,, S.Groshen,, and D.A.Berry, 2013Bayesian Hierarchical Modeling of Patient Subpopulations: Efficient Designs of Phase II Oncology Clinical Trials,” Clinical Trials, 10, 720–734.
4. K.Broglio, Kr., and D.A.Berry, 2009Detecting an Overall Survival Benefit That is Derived From Progression-Free Survival,” JNCI Journal of the National Cancer Institute, 101:1642–1649.
5. Brookings events Discussion Guide (2014), Expert Workshop: Pioneering Statistical Approaches to Accelerate Drug Development through Adaptive Trial Designs, available at. http://www.brookings.edu/∼/media/events/2014/3/27-adaptive-trial-design-clinical-trials/discussion-guide.pdf
6. M.Buyse, 2000Randomized Designs for Early Trials of New Cancer Treatments—An Overview,” Drug Information Journal, 34, 387–396.
7. P.Cortazar,, L.Zhang,, M.Untch,, K.Mehta,, J.P.Costantino,, N.Wolmark,, H.Bonnefoi,, D.Cameron,, L.Gianni,, P.Valagussa,, S.M.Swain,, T.Prowell,, S.Loibl,, D.L.Wickerham,, J.Bogaerts,, J.Baselga,, C.Perou,, G.Blumenthal,, J.Blohmer,, E.P.Mamounas,, J.Bergh,, V.Semiglazov,, R.Justice,, H.Eidtmann,, S.Paik,, M.Piccart,, R.Sridhara,, P.A.Fasching,, L.Slaets,, S.Tang,, B.Gerber,, C.E.J.Geyer, C. E. Jr., R.Pazdur,, N.Ditsch,, P.Rastogi,, W.Eiermann,, and G.von Minckwitz, 2014Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis,” Lancet, 384, 164–172.
8. R.B.D’Agostino, Jr. 1998Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Nonrandomized Control Group,” Statistics in Medicine, 17, 2265–2281.
9. S.E.Dahlberg,, G.I.Shapiro,, J.W.Clark,, and B.E.Johnson, 2014Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience,” JNCI, 106, 1–6.
10. FDA 2012Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf
11. ——— 2014Guidance for Industry Expedited Programs for Serious Conditions—Drugs and Biologics, available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf
12. Food and Drug Safety Innovation Act (2012), available at http://www.gpo.gov/fdsys/pkg/BILLS-112s3187enr/pdf/BILLS-112s3187enr.pdf
13. R.J.Gray, 1988A Class of K-Sample Tests for Comparing the Cumulative Incidence of Competing Risks,” Annals of Statistics, 16, 1141–1154.
14. Guidance for Industry Pathological 2014Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval, available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf
15. M.C.Heinrich,, H.Joensuu,, G.D.Demetri,, C.L.Corless,, J.Apperley,, J.A.Fletcher,, D.Soulieres,, S.Dirnhofer,, A.Harlow,, A.Town,, A.McKinley,, S.G.Supple,, J.Seymour,, L.DiScala,, A.van Oosterom,, R.Herrmann,, Z.Nikolova,, A.G.McArthur,, and Imatinib Target Exploration Consortium Study B2225 2008Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to be Associated With Imatinib-Sensitive Tyrosine Kinases,” Clinical Cancer Research, 14, 2717–2725.
16. R.S.Herbst,, D.R.Gandara,, F.R.Hirsch,, M.W.Redman,, M.LeBlanc,, P.C.Mack,, L.H.Schwartz,, E.Vokes,, S.S.Ramalingam,, J.D.Bradley,, D.Sparks,, Y.Zhou,, C.Miwa,, V.A.Miller,, R.Yelensky,, Y.Li,, J.D.Allen,, E.V.Sigal,, D.Wholley,, C.C.Sigman,, G.M.Blumenthal,, S.Malik,, G.J.Kelloff,, J.S.Abrams,, C.D.Blanke,, and V.A.Papadimitrakopoulou, 2015Lung Master Protocol (Lung MAP) – A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400,’’ Clinical Cancer Research, 21, 1514–1524.
17. R.S.Herbst,, D.Gandara,, and V.Papadimitrakopoulou, 2015How the Lung-MAP Clinical Trial is Responding to Changing Science,” The Cancer Letter, 41, 12–15.
18. S.P.Hey,, and J.Kimmelman, 2015Are Outcome-Adaptive Allocation Trials Ethical?" Clinical Trials, 12, 102–106.
19. J.Hintze, (2013), Power Analysis & Sample Size Software® PASS 12, Kaysville, UT: NCSS, LLC. Available at www.ncss.com.
20. F.S.Hodi,, S.J.O’Day,, D.F.McDermott,, R.W.Weber,, J.A.Sosman,, J.B.Haanen,, R.Gonzalez,, C.Robert,, D.Schadendorf,, J.C.Hassel,, W.Akerley,, A.J.van den Eertwegh,, J.Lutzky,, P.Lorigan,, J.M.Vaubel,, G.P.Linette,, D.Hogg,, C.H.Ottensmeier,, C.Lebbé,, C.Peschel,, I.Quirt,, J.I.Clark,, J.D.Wolchok,, J.S.Weber,, J.Tian,, M.J.Yellin,, G.M.Nichol,, A.Hoos,, and W.J.Urba, 2010Improved Survival With Ipilimumab in Patients With Metastatic Melanoma,” New England Journal of Medicine, 363, 711–723.
21. M.K.Kelley,, and S.W.Abdus, 2013Weighted Log-Rank Statistic to Compare Shared-Path Adaptive Treatment Strategies,” Biostatistics, 14, 299–312.
22. E.S.Kim,, R.S.Herbst,, I.I.Wistuba,, J.J.Lee,, G.R.Blumenschein,, Jr., A.Tsao,, D.J.Stewart,, M.E.Hicks,, J.J.Erasmus, Jr. J., S.Gupta,, C.M.Alden,, S.Liu,, X.Tang,, F.R.Khuri,, H.T.Tran,, B.E.Johnson,, J.V.Heymach,, L.Mao,, F.Fossella,, M.S.Kies,, V.Papadimitrakopoulou,, S.E.Davis,, S.M.Lippman,, and W.K.Hong, 2011The BATTLE Trial: Personalizing Therapy for Lung Cancer,” Cancer Discovery, 1, 44–53.
23. N.R.Latimer,, K.R.Abrams,, P.C.Lambert,, M.Crowther,, A.Wailoo,, J.Morden,, R.Akehurst,, and M.Campbell, 2014Adjusting for Treatment Switching in Randomized Controlled Trials—A Simulation Study and a Simplified Two-Stage Method,” Statistical Methods in Medical Research, 0, 1–28.
24. L.LaVange,, and R.Sridhara, 2014Statistical Considerations in Designing Master Protocols,'' in Presented at Innovations in Breast Cancer Drug Development—Next Generation Oncology Trials, Breast Cancer Workshop. Available at http://www.fda.gov/downloads/Drugs/NewsEvents/UCM423368.pdf
25. Z.Li,, M.Valenstein,, P.Pfeiffer,, and D.Ganoczy, 2014A Global Logrank Test for Adaptive Treatment Strategies Based on Observational Studies,” Statistics in Medicine, 28, 760–771.
26. Y.Lokhnygina,, and J.D.Helterbrand, 2007 Cox Regression Methods for Two-Stage Randomization Designs,” Biometrics, 63, 422–428.
27. A.Lopez-Chavez,, A.Tomas,, M.Raffeld,, B.Morrow,, R.Kelly,, C.A.Carter,, U.Guha,, K.Killian,, C.C.Lau,, Z.Abdullaev,, L.Xi,, S.Pack,, P.S.Meltzer,, C.L.Corless,, A.Sandler,, C.Beadling,, A.Warrick,, D.J.Liewehr,, S.M.Steinberg,, A.Berman,, A.Doyle,, E.Szabo,, Y.Wang,, and G.Giaccone, 2015 Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial,” Journal of Clinical Oncology, 33, 1000–1007.
28. J.K.Lunceford,, and M.Davidian, 2004 Stratification and Weighting via the Propensity Score in Estimation of Causal Treatment Effects: A Comparative Study,” Statistics in Medicine, 23, 2937–2960.
29. T.S.Mok,, W.YuL., W.Y.L.W., S.Thogprasert,, C.H.Yang,, D.T.Chu,, N.Saijo,, P.Sunpaweravong,, B.Han,, B.Margono,, Y.Ichinose,, Y.Nishiwaki,, Y.Ohe,, J.J.Yang,, B.Chewaskulyong,, H.Jiang,, E.L.Duffield,, C.L.Watkins,, A.A.Armour,, and M.Fukuoka,2009 Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma,” New England Journal of Medicine, 361, 947–957.
30. National Cancer Institute, A Joint NCTN/NCI Clinical Trial (2015), Molecular Analysis of Therapy Choice, available at. http://dctd.cancer.gov/MajorInitiatives/NCI-MATCH.pdf
31. Rituxan US Package Insert (2014), Prescribing Information RITUXAN®. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf
32. C.Robert,, L.Thomas,, I.Bondarenko,, S.O'Day,, J.Weber,, C.Garbe,, C.Lebbe,, J.F.Baurain,, A.Testori,, J.J.Grob,, N.Davidson,, J.Richards,, M.Maio,, A.Hauschild,, W.H.J.Miller, W. H. Jr., P.Gascon,, M.Lotem,, K.Harmankaya,, R.Ibrahim,, S.Francis,, T.T.Chen,, R.Humphrey,, A.Hoos,, and J.D.Wolchok, 2011 Ipilimumab Plus Dacarbazine for Previously Untreated Metastatic Melanoma,” New England Journal of Medicine, 364, 2517–2526.
33. J.M.Robins,, M.A.Hernan,, and B.Brumback, 2000 Marginal Structural Models and Causal Inference in Epidemiology,” Epidemiology, 11, 550–560.
34. H.Uno,, B.Claggett,, L.Tian,, E.Inoue,, P.Gallo,, T.Miyata,, D.Schrag,, M.Takeuchi,, Y.Uyama,, L.Zhao,, H.Skali,, S.Solomon,, S.Jacobus,, M.Hughes,, M.Packer,, and L.J.Wei, 2014 Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis,” Journal of Clinical Oncology, 32, 2380–2385.
35. A.Wong,, W.Leaf-Herrmann,, and L.W.Leahy, 2014 Novel Clinical Trial Designs in Oncology: An Histology-Independent Approach, IN VIVO: The Business & Medicine Report May 2014,’’. available at http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/novel_clinical_trial_designs_in_oncology.pdf
36. J.Xie,, and C.Liu, 2005 Adjusted Kaplan-Meier Estimator and Log-Rank Test With Inverse Probability of Treatment Weighting for Survival Data,” Statistics in Medicine, 24, 3089–3110.
37. Z.Zhang, 2007 Estimating the Current Treatment Effect With Historical Control Data,” JP Journal of Biostatistics, 1, 217–247.
38. D.Zhang,, and H.Quan, 2009 Power and Sample Size Calculation for Log-Rank Test With a Time Lag in Treatment Effect,” Statistics in Medicine, 28, 864–879.
39. L.Zhang,, C.Ko,, S.Tang,, and R.Sridhara, 2013Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study,” Therapeutic Innovation & Regulatory Science, 47, 95–100.